Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs MakeMyTrip Ltd (MMYT) Price & Performance

Cassava Sciences IncTrade
MakeMyTrip LtdTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs MakeMyTrip Ltd — how do they compare? Cassava Sciences Inc trades at $0.95 (market cap $47.75M), while MakeMyTrip Ltd trades at $60.56 (market cap $5.78B). The key difference: MakeMyTrip Ltd is far larger — about 121× Cassava Sciences Inc's market cap, and MakeMyTrip Ltd is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

FLNAMMYT
Market Cap
$47.75M$5.78B
Sector
HealthTechnology
52-Week High
$4.64$103.21
52-Week Low
$0.87$36.30
Enterprise Value
-$34.93M$6.44B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

MakeMyTrip Ltd

MakeMyTrip (MMYT) trades at $60.31, down 0.99% today, with a bullish technical signal supported by moving averages. The company shows strong revenue growth to $978M in 2025 and consistent earnings beats, though Q2 2026 missed expectations. Analyst sentiment remains positive with 73% buy ratings and a 34% upside target. Recent news highlights travel industry momentum despite temporary air-ticketing softness.

Investment outlook appears favorable with strong fundamentals and bullish analyst consensus, though risks include rising debt levels and geopolitical travel disruptions. The stock's high P/E ratio of 267 requires sustained earnings growth to justify valuation. Recent institutional selling by Boston Common Asset Management warrants monitoring for broader sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About MakeMyTrip Ltd

MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.

Read more on MMYT